LIMAA Technologies Appoints Prof. Dr. med. Jörg Debatin as Chairman of the Board
Prof. Dr. med. Jörg Debatin, new LIMAA Technologies Chairman, visiting our lab – quote on team collaboration in digital pathology
Cologne, 11.03.2026 – LIMAA Technologies GmbH is pleased to announce the appointment of Prof. Dr. med. Jörg Debatin as Chairman of the Board. This strategic step marks an important milestone in LIMAA’s transition into a commercial-stage organization.
Prof. Debatin brings decades of leadership experience in healthcare, diagnostics, and medical technology. He has a strong track record in strategic health-tech leadership, governance, and organizational scaling. His extensive international network across healthcare, industry, and policy will play a key role in guiding LIMAA’s next phase of growth.
Jörg Debatin: “I am looking forward to working with a top-notch team of scientists and engineers dedicated to fundamentally improving efficiency and accuracy of tissue-based diagnosis.”
Jörg Debatin is widely recognized for shaping and advancing healthcare systems at scale. He served as Chief Executive Officer of the University Medical Center Hamburg-Eppendorf, where he drove institutional development and strategic positioning. At Amedes Group, one of Europe’s leading laboratory diagnostics providers, he accelerated growth and sharpened the company’s strategic focus. During his tenure at GE Healthcare, he contributed to global innovation initiatives and international market expansion. In addition, he played a pivotal role in Germany’s national digital health strategy as Chairman of the Federal Ministry of Health’s Health Innovation Hub.
Fabian Mohr, Co-Founder and CEO of LIMAA Technologies, commented:
“Jörg’s proven track record in building and scaling healthcare organizations aligns strongly with our vision to deliver pathology solutions that truly make a difference in our customers’ daily work. His strategic perspective and deep industry understanding will be invaluable as we expand our commercial footprint.”
With this appointment, LIMAA strengthens its governance structure. The company is positioning itself to accelerate product development and the market entry of its innovative pathology solutions.
About LIMAA Technologies GmbH
LIMAA Technologies GmbH is a deep-tech spinoff from Charité University Hospital. The company is developing an end-to-end, fully automated histology platform that enhances diagnostic efficiency and accuracy. To that end, LIMAA is developing and commercializing reagents, hardware, and software that generate high-resolution native digital images of tissue specimens. By making this cutting-edge technology platform available to healthcare providers worldwide, LIMAA aims to greatly facilitate tissue-based diagnosis.